Astal Laboratories Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 09/10/2025 ,inter alia, to consider and approve 1) To increase authorised ....
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Astal Laboratories has called a board meeting on October 9, 2025 to consider increasing the authorised share capital of the company. The board will also evaluate issuing equity shares or convertible warrants on a preferential basis to certain investors. Separately, the board will take a final decision on acquiring 100% of M/s Sriven Pharmachem India Private Limited (SPIPL). The company will also adopt the draft notice and fix the date for an Extra Ordinary General Meeting (EGM) to seek shareholder approval for these moves. The trading window for insiders is already closed from October 1, 2025 until 48 hours after the Q2 FY26 results are declared.
The preferential share issue could lead to dilution for existing shareholders, while the proposed 100% acquisition of Sriven Pharmachem signals a possible expansion move. The stock may see volatility around the board meeting date on October 9, 2025 as these are material corporate actions.